Spots Global Cancer Trial Database for pembrolizumab injection [keytruda]
Every month we try and update this database with for pembrolizumab injection [keytruda] cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | NCT05033756 | Malignant Neopl... Breast Cancer | Pembrolizumab I... Olaparib Oral T... | 18 Years - | Institut fuer Frauengesundheit | |
| Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma | NCT04813523 | Adenocarcinoma ... Neoadjuvant Che... Pembrolizumab | Pembrolizumab I... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. | |
| Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant | NCT04425226 | Liver Transplan... Hepatocellular ... | Pembrolizumab I... Lenvatinib Oral... | 18 Years - 80 Years | RenJi Hospital | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | NCT04389177 | Esophageal Squa... Stage III | Pembrolizumab I... | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | NCT03311308 | Advanced Melano... | Pembrolizumab I... Metformin | 18 Years - | University of Pittsburgh | |
| Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC | NCT05096390 | Papillary Renal... | Axitinib Oral T... Pembrolizumab I... | 18 Years - | Centre Leon Berard | |
| SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy | NCT04931979 | Urologic Cancer Biochemical Rec... | Pembrolizumab I... Salvage Radiati... | 18 Years - | University Hospital Freiburg | |
| Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma | NCT04813523 | Adenocarcinoma ... Neoadjuvant Che... Pembrolizumab | Pembrolizumab I... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | NCT04659629 | Solid Tumor Advanced Solid ... | NL-201 Pembrolizumab I... | 18 Years - | Neurogene Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
